Renal cell carcinoma (RCC) represents the seventh (men) respectively tenth (women) most frequent cancer in western countries. After one or more lines of VEGF-targeted therapy, immunotherapy with nivolumab is strongly recommended in patients with metastatic RCC. Nivolumab is the first, and so far, only approved programmed death 1 (PD-1) immune checkpoint inhibitor to demonstrate a gain in overall survival in RCC. We describe herein design and rationale of trial CA209653 ('NIS NORA'), a prospective, noninterventional cohort study investigating the effectiveness of nivolumab. This systematic collection of real-world effectiveness data will recruit 323 patients with advanced RCC to provide a precise estimate for overall survival over a 5-year follow-up period (Trial registration: NCT02940639).
Future oncology (London, England). 2018 Jan 12 [Epub ahead of print]
Jens Bedke, Marc-Oliver Grimm, Viktor Grünwald
Department of Urology, University Hospital Tübingen, Tübingen, Germany., Department of Urology, Jena University Hospital, Jena, Germany., Department of Hematology, Hemostasis, Oncology & Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.